PT - JOURNAL ARTICLE AU - Cai, Guoshuai TI - Tobacco-use disparity in gene expression of ACE2, the receptor of 2019-nCov AID - 10.1101/2020.02.05.20020107 DP - 2020 Jan 01 TA - medRxiv PG - 2020.02.05.20020107 4099 - http://medrxiv.org/content/early/2020/02/11/2020.02.05.20020107.short 4100 - http://medrxiv.org/content/early/2020/02/11/2020.02.05.20020107.full AB - In current severe global emergency situation of 2019-nCov outbreak, it is imperative to identify vulnerable and susceptible groups for effective protection and care. Recently, studies found that 2019-nCov and SARS-nCov share the same receptor, ACE2. In this study, we analyzed four large-scale datasets of normal lung tissue to investigate the disparities related to race, age, gender and smoking status in ACE2 gene expression. No significant disparities in ACE2 gene expression were found between racial groups (Asian vs Caucasian), age groups (>60 vs <60) or gender groups (male vs female). However, we observed significantly higher ACE2 gene expression in smoker samples compared to non-smoker samples. This indicates the smokers may be more susceptible to 2019-nCov and thus smoking history should be considered in identifying susceptible population and standardizing treatment regimen.Competing Interest StatementThe authors have declared no competing interest.Funding StatementNoneAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesTwo RNA-seq datasets and two DNA microarray datasets from lung cancer patients were analyzed in this study, including a Caucasian RNA-seq dataset from TCGA (https://www.cancer.gov/tcga), an Asian RNA-seq dataset from Gene Expression Omnibus (GEO) with the accession number GSE40419, an Asian microarray dataset from GEO with the accession number GSE19804 and a Caucasian microarray dataset from GEO with the accession number GSE10072.